Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Early Phase 1:1
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (50.0%)Phase 1
1 (50.0%)A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Early Phase 1
Recruiting
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Drug: lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Blue Earth Therapeutics Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06516510
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Madrid, Spain
🇺🇸Biogenix Molecular, Miami, Florida, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Phase 1
Recruiting
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate CancermCRPCUrogenital NeoplasmsProstatic NeoplasmsProstatic Diseases
- Interventions
- Drug: Lutetium (177Lu) rhPSMA-10.1 InjectionDiagnostic Test: 18F-rhPSMA-7.3 injection (in phase 1 only)
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Blue Earth Therapeutics Ltd
- Target Recruit Count
- 82
- Registration Number
- NCT05413850
- Locations
- 🇺🇸
Biogenix Molecular, Miami, Florida, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸XCancer Omaha / Urology Cancer Center, Omaha, Nebraska, United States
News
No news found